<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02727296</url>
  </required_header>
  <id_info>
    <org_study_id>VAPOR-002</org_study_id>
    <nct_id>NCT02727296</nct_id>
  </id_info>
  <brief_title>Volatile Anesthetic Protection Of Renal Transplants 2</brief_title>
  <acronym>VAPOR-2</acronym>
  <official_title>Volatile Anesthetic Protection Of Renal Transplants 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gertrude J. Nieuwenhuijs-Moeke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effect of a sevoflurane based anesthesia versus a propofol based anesthesia on
      the incidence of DGF in recipients of kidneys of donation after circulatory death (DCD) and
      donation after brain death (DBD) donors
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective:

      To compare the effect of a sevoflurane based anaesthesia versus a propofol based anaesthesia
      on the incidence of delayed graft function in recipients of DCD and DBD donor kidneys.

      Study design:

      Prospective randomized controlled European multicentre clinical trial with two parallel
      groups

      Study population:

      Patients â‰¥18 years scheduled for kidney transplantation with a kidney from a DBD or DCD donor

      Intervention:

      Patients will be included and randomised to one of the following groups:

      Group 1 PROP (control): Propofol: a propofol-remifentanil based anaesthesia. Group 2 SEVO
      (intervention): Sevoflurane: a sevoflurane-remifentanil based anaesthesia.

      Main study parameters:

      DGF defined as need of dialysis the first week after transplantation excluding one time
      dialysis for hyperkalemia Acute rejection episodes within the first year after
      transplantation Graft and patient survival GFR at 3 and 12 months PNF defined as a permanent
      lack of function of the allograft Length of hospital stay Postoperative complications of all
      kind kidney biomarkers (urine/plasma) mechanisms of protection/immunomodulation with
      anestheticanaesthetic agents
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of delayed graft function</measure>
    <time_frame>during first week after transplantation</time_frame>
    <description>DGF is defined as need of dialysis first 7 days after transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glomerular Filtration Rate (GFR)</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>GFR will be calculated with the use of a 24h creatinin clearance in urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute rejection</measure>
    <time_frame>during first year after transplantation</time_frame>
    <description>biopsy proven with decline in kidney function and therapy needed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of primary non function (PNF)</measure>
    <time_frame>first three months after transplantation</time_frame>
    <description>PNF is defined as permanent lack of function of the transplanted kidney. This kidney will not gain function after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>kidney injury urinary biomarkers</measure>
    <time_frame>first week after transplantation</time_frame>
    <description>a set of kidney urinary biomarkers will be measured in urinary samples</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">488</enrollment>
  <condition>Delayed Graft Function</condition>
  <condition>Renal Outcome After Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 1 PROP (control): propofol: a propofol-remifentanil based general anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sevoflurane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2 SEVO (intervention): Sevoflurane: a sevoflurane-remifentanil based general anesthesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sevoflurane</intervention_name>
    <description>General anesthesia with sevoflurane</description>
    <arm_group_label>sevoflurane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol</intervention_name>
    <description>General anesthesia with propofol</description>
    <arm_group_label>propofol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Written informed consent

        Exclusion Criteria:

          -  high immunological risk as determined bij local practice

          -  Patients of the ABO-incompatible program
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gertrude J Nieuwenhuijs-Moeke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gertrude J Nieuwenhuijs-Moeke, MD</last_name>
    <phone>+31631623075</phone>
    <email>g.j.nieuwenhuijs-moeke@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rob Spanjersberg</last_name>
    <phone>+31503611158</phone>
    <email>r.spanjersberg@umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9728XR</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gertrude Nieuwenhuijs-Moeke, MD</last_name>
      <phone>+31631623075</phone>
      <email>g.j.nieuwenhuijs-moeke@umcg.nl</email>
    </contact>
    <contact_backup>
      <last_name>Rob Spanjersberg</last_name>
      <phone>+31640365855</phone>
      <email>r.spanjersberg@umcg.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2016</study_first_submitted>
  <study_first_submitted_qc>April 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2016</study_first_posted>
  <last_update_submitted>November 9, 2017</last_update_submitted>
  <last_update_submitted_qc>November 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Gertrude J. Nieuwenhuijs-Moeke</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delayed Graft Function</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

